Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

As diverse therapeutic options are now available for advanced melanoma patients, predictive markers that may assist treatment decision are needed. A model based on baseline serum lactate dehydrogenase (LDH), peripheral blood relative lymphocyte counts (RLC) and eosinophil counts (REC) and pattern of distant metastasis, has been recently proposed for pembrolizumab-treated patients. Here, we applied this model to advanced melanoma patients receiving chemotherapy (n = 116) or anti- CTLA-4 therapy (n = 128). Visceral involvement, LDH and RLC were associated with prognosis regardless of treatment. Instead, when compared to chemotherapy-treated patients with REC < 1.5%, those with REC ≥ 1.5% had improved overall survival when receiving anti-CTLA-4 [Hazard Ratio (HR) = 0.56 (0.4-0.93)] but not chemotherapy [HR = 1.13, (0.74-1.74)], and the treatment-by-REC interaction was significant for both overall (p = 0.04) and progression free survival (p = 0.009). These results indicate baseline REC ≥ 1.5% as a candidate predictive biomarker for benefit from anti-CTLA-4. Further studies are needed to confirm these findings in patients receiving immune-modulating agents.

Original languageEnglish
Pages (from-to)79809-79815
Number of pages7
JournalOncotarget
Volume8
Issue number45
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Eosinophils
Melanoma
Biomarkers
Lymphocyte Count
L-Lactate Dehydrogenase
Drug Therapy
Therapeutics
Disease-Free Survival
ipilimumab
Neoplasm Metastasis
Survival
Serum

Keywords

  • Biomarker
  • Eosinophil
  • Ipilimumab
  • Melanoma
  • Predictive

ASJC Scopus subject areas

  • Oncology

Cite this

Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma. / Ferrucci, Pier Francesco; Gandini, Sara; Cocorocchio, Emilia; Pala, Laura; Baldini, Federica; Mosconi, Massimo; Cappellini, Gian Carlo Antonini; Albertazzi, Elena; Martinoli, Chiara.

In: Oncotarget, Vol. 8, No. 45, 01.01.2017, p. 79809-79815.

Research output: Contribution to journalArticle

@article{546948ef38014e10ac23f95058ed18eb,
title = "Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma",
abstract = "As diverse therapeutic options are now available for advanced melanoma patients, predictive markers that may assist treatment decision are needed. A model based on baseline serum lactate dehydrogenase (LDH), peripheral blood relative lymphocyte counts (RLC) and eosinophil counts (REC) and pattern of distant metastasis, has been recently proposed for pembrolizumab-treated patients. Here, we applied this model to advanced melanoma patients receiving chemotherapy (n = 116) or anti- CTLA-4 therapy (n = 128). Visceral involvement, LDH and RLC were associated with prognosis regardless of treatment. Instead, when compared to chemotherapy-treated patients with REC < 1.5{\%}, those with REC ≥ 1.5{\%} had improved overall survival when receiving anti-CTLA-4 [Hazard Ratio (HR) = 0.56 (0.4-0.93)] but not chemotherapy [HR = 1.13, (0.74-1.74)], and the treatment-by-REC interaction was significant for both overall (p = 0.04) and progression free survival (p = 0.009). These results indicate baseline REC ≥ 1.5{\%} as a candidate predictive biomarker for benefit from anti-CTLA-4. Further studies are needed to confirm these findings in patients receiving immune-modulating agents.",
keywords = "Biomarker, Eosinophil, Ipilimumab, Melanoma, Predictive",
author = "Ferrucci, {Pier Francesco} and Sara Gandini and Emilia Cocorocchio and Laura Pala and Federica Baldini and Massimo Mosconi and Cappellini, {Gian Carlo Antonini} and Elena Albertazzi and Chiara Martinoli",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.19748",
language = "English",
volume = "8",
pages = "79809--79815",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "45",

}

TY - JOUR

T1 - Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma

AU - Ferrucci, Pier Francesco

AU - Gandini, Sara

AU - Cocorocchio, Emilia

AU - Pala, Laura

AU - Baldini, Federica

AU - Mosconi, Massimo

AU - Cappellini, Gian Carlo Antonini

AU - Albertazzi, Elena

AU - Martinoli, Chiara

PY - 2017/1/1

Y1 - 2017/1/1

N2 - As diverse therapeutic options are now available for advanced melanoma patients, predictive markers that may assist treatment decision are needed. A model based on baseline serum lactate dehydrogenase (LDH), peripheral blood relative lymphocyte counts (RLC) and eosinophil counts (REC) and pattern of distant metastasis, has been recently proposed for pembrolizumab-treated patients. Here, we applied this model to advanced melanoma patients receiving chemotherapy (n = 116) or anti- CTLA-4 therapy (n = 128). Visceral involvement, LDH and RLC were associated with prognosis regardless of treatment. Instead, when compared to chemotherapy-treated patients with REC < 1.5%, those with REC ≥ 1.5% had improved overall survival when receiving anti-CTLA-4 [Hazard Ratio (HR) = 0.56 (0.4-0.93)] but not chemotherapy [HR = 1.13, (0.74-1.74)], and the treatment-by-REC interaction was significant for both overall (p = 0.04) and progression free survival (p = 0.009). These results indicate baseline REC ≥ 1.5% as a candidate predictive biomarker for benefit from anti-CTLA-4. Further studies are needed to confirm these findings in patients receiving immune-modulating agents.

AB - As diverse therapeutic options are now available for advanced melanoma patients, predictive markers that may assist treatment decision are needed. A model based on baseline serum lactate dehydrogenase (LDH), peripheral blood relative lymphocyte counts (RLC) and eosinophil counts (REC) and pattern of distant metastasis, has been recently proposed for pembrolizumab-treated patients. Here, we applied this model to advanced melanoma patients receiving chemotherapy (n = 116) or anti- CTLA-4 therapy (n = 128). Visceral involvement, LDH and RLC were associated with prognosis regardless of treatment. Instead, when compared to chemotherapy-treated patients with REC < 1.5%, those with REC ≥ 1.5% had improved overall survival when receiving anti-CTLA-4 [Hazard Ratio (HR) = 0.56 (0.4-0.93)] but not chemotherapy [HR = 1.13, (0.74-1.74)], and the treatment-by-REC interaction was significant for both overall (p = 0.04) and progression free survival (p = 0.009). These results indicate baseline REC ≥ 1.5% as a candidate predictive biomarker for benefit from anti-CTLA-4. Further studies are needed to confirm these findings in patients receiving immune-modulating agents.

KW - Biomarker

KW - Eosinophil

KW - Ipilimumab

KW - Melanoma

KW - Predictive

UR - http://www.scopus.com/inward/record.url?scp=85030472711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030472711&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.19748

DO - 10.18632/oncotarget.19748

M3 - Article

AN - SCOPUS:85030472711

VL - 8

SP - 79809

EP - 79815

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 45

ER -